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ARTICLE
Microbiota-driven interleukin-17-producing cells
and eosinophils synergize to accelerate multiple
myeloma progression
Arianna Calcinotto1,12, Arianna Brevi1,2, Marta Chesi 3, Roberto Ferrarese4, Laura Garcia Perez5,
Matteo Grioni1, Shaji Kumar 6, Victoria M. Garbitt3, Meaghen E. Sharik3, Kimberly J. Henderson6,
Giovanni Tonon7, Michio Tomura8, Yoshihiro Miwa9, Enric Esplugues10, Richard A. Flavell 10, Samuel Huber5,
Filippo Canducci 4,11, Vincent S. Rajkumar6, P. Leif Bergsagel 3 & Matteo Bellone 1
The gut microbiota has been causally linked to cancer, yet how intestinal microbes inﬂuence
progression of extramucosal tumors is poorly understood. Here we provide evidence implying
that Prevotella heparinolytica promotes the differentiation of Th17 cells colonizing the gut and
migrating to the bone marrow (BM) of transgenic Vk*MYC mice, where they favor pro-
gression of multiple myeloma (MM). Lack of IL-17 in Vk*MYC mice, or disturbance of their
microbiome delayed MM appearance. Similarly, in smoldering MM patients, higher levels of
BM IL-17 predicted faster disease progression. IL-17 induced STAT3 phosphorylation in
murine plasma cells, and activated eosinophils. Treatment of Vk*MYC mice with antibodies
blocking IL-17, IL-17RA, and IL-5 reduced BM accumulation of Th17 cells and eosinophils and
delayed disease progression. Thus, in Vk*MYC mice, commensal bacteria appear to unleash a
paracrine signaling network between adaptive and innate immunity that accelerates pro-
gression to MM, and can be targeted by already available therapies.
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While many factors regulating cancer progression aretumor cell autonomous, they are insufﬁcient to induceprogression to malignancy. Among the cell-extrinsic
drivers of cancer, a strong link has been proposed between diet,
commensal bacteria, and aerodigestive tract malignancies1.
Microbes within the gut also contribute to carcinogenesis at
mucosal sites by altering the balance of epithelial cell proliferation
and death, by favoring the production of toxic metabolites from
host-produced factors and drugs, and by promoting chronic
inﬂammation and/or local immune suppression1.
As the microbiome of each organ is distinct, the effects on
inﬂammation and carcinogenesis are likely to be organ speciﬁc2.
Nevertheless, gut commensal bacteria are involved in the patho-
genesis of extramucosal autoimmune diseases3, thus supporting
the role of the gut microbiota in shaping systemic immune
responses. Yet, the mechanisms by which non-pathogenic
microbes drive non-aerodigestive tract malignancies remain to
be elucidated.
Commensal bacteria are involved in the differentiation of Th17
cells4, which mainly produce IL-17A (also deﬁned IL-17), IL-17F,
and IL-22, all cytokines playing a critical role in inﬂammation5.
The role of Th17 cells in cancer is controversial. While some
authors showed that Th17 cells were efﬁcient in eliminating
tumors6, others reported accumulation of Th17 cells in
several tumors, in which they promoted tumor initiation7 and
progression8.
In multiple myeloma (MM), a B cell neoplasm characterized by
the accumulation of clonal plasma cells within the bone marrow
(BM), and in most cases a monoclonal protein (i.e., M-spike) in
blood and/or urine, Th17 cells have been linked to advanced
disease with bone lesions9. Of relevance, IL-17 can promote
tumor growth through an IL-6-STAT3 signaling pathway10,
which is also pivotal for plasma cell growth11, thus suggesting a
role for IL-17 in different phases of MM.
No data are available on the potential role of IL-17-producing
cells in the early, asymptomatic phases of MM, and on the
mechanisms by which IL-17-producing cells are induced and/or
recruited in the BM of MM patients. Smoldering multiple mye-
loma (SMM) is an asymptomatic phase that may anticipate full-
blown MM. The deﬁnition of SMM has been proposed to ﬁll the
gray zone between monoclonal gammopathy of undetermined
signiﬁcance (MGUS), a rather common ﬁnding in the elders, and
active MM. Indeed, patients affected by SMM are subjected to
more frequent follow-up than MGUS because they have a much
higher risk of progression12. However, likely because of hetero-
geneity in the pathobiology of the disease and lack of adequate
risk stratiﬁcation, few interventional studies in SMM patients
have shown improved overall survival with therapy13. Indeed,
most of the accepted clinical parameters to deﬁne high-risk SMM
are evidence-based13. This paradigm would beneﬁt from a shift
that focuses more on the early modiﬁcations in the cellular and
molecular composition of the BM microenvironment, thus to
identify biological culprits of aggressiveness.
We selected MM as a prototypic extramucosal cancer, and
investigated here the potential link between gut microbiota, IL-17
and the progression from asymptomatic SMM to active MM.
Results
P. heparinolytica favors MM progression. To investigate the link
between intestinal microbes and extraintestinal cancers, Vk*MYC
mice, which develop a de novo disease mimicking MM14, were
housed in animal facilities located in USA (US) and Italy (IT),
and monitored within the years 2012–2018 for disease appear-
ance and the presence of M-spike by serum protein electro-
phoresis14. While a monoclonal M-spike was readily detectable by
20 weeks of age in the blood of about 30% Vk*MYC mice housed
in US1 and monitored before 2014, age-matched and sex-
matched Vk*MYC mice from US2 (monitored after 2015) or IT
(monitored between 2012 and 2018) did not show signs of disease
for another 10–15 weeks, a time at which more than 60% of the
Vk*MYC mice from the US1 colony had a detectable M-spike
(Fig. 1a). Irrespective of the animal facility of origin, age-matched
and sex-matched wild type (WT) mice, as expected15, developed
M-spikes much later than Vk*MYC (Fig. 1a), and never devel-
oped MM (see Fig. 2b). These ﬁndings suggested that the envir-
onment, and the microbiota in particular, has a pathogenic
impact only on those mice whose plasma cells carry driver genetic
alterations like the MYC activation, and is not sufﬁcient per se to
generate the disease in otherwise healthy mice with spontaneous
monoclonal gammopathy.
To identify constituents of the microbiota, stools simulta-
neously collected from mice housed in the different animal
facilities before 2014 and after 2015 were subjected to 16S rDNA-
based amplicon sequencing. We did not observe statistically
signiﬁcant differences between US1, US2, and IT samples in
terms of intra-sample observed species (α-diversity) by Shannon
or CHAO1 indexes (Supplementary Fig. 1). Unweighted UniFrac
principal component analyses (β-diversity) clearly segregated the
three cohorts of mice, and showed large differences in bacterial
species between US1 and US2 or IT mice, irrespective of being
Vk*MYC or WT (Fig. 1b). Main diversities were found within 8
taxa (Fig. 1c), belonging to the two major phyla hosted in most
mammals: Gram negative Bacteroidetes and Gram positive
Firmicutes16. More in details, Bacteroidetes (Bacteroidaceae,
Prevoltellaceae, Rikenellaceae, and S24–7) were more represented
in the feces of US1 animals (approximately 80% in US1, 56% in
US2 and 65% in IT), while US2 and IT animals were more
colonized by Firmicutes (Clostridiales; 1.62 ± 1.3% in US1; 9.46 ±
8.7% in US2, and 7.6 ± 4% in IT). Health reports conﬁrmed the
absence of relevant pathogens in the animal facilities, US1 and
US2 mice were housed at the same institution, and changes in the
microbiota were not apparently related to the diet, because US1
and US2 were fed the same diet (i.e., PicoLab® Rodent Diet 20
5053; LabDiet), whose content of nutrients, minerals, vitamins
and calories was comparable to the diet of IT mice (Teklad Global
18% Protein Rodent Diet; Harlan). The documented changes in
the microbiota were likely due instead to the different breeding
strategies adopted in US1 and US2 (Fig. 1b). Whereas Vk*MYC
breeding in US1 was made by crossing Vk*MYC with WT
littermates, the US2 colony was generated by breeding Vk*MYC
with C57BL/6J mice from the Jackson Lab. Thus, the microbiota
imported from the purchased mice might have modiﬁed the
microbiota in the US2 colony.
We sought a direct causative role of the microbiota in favoring
MM development by treating IT WT mice with a combination of
different wide-spectrum antibiotics (ciproﬂoxacin and metroni-
dazole), and by leaving a group untreated. To perform a
controlled study on genetically homogeneous tumors, antibiotic
treated and untreated mice were challenged with Vk*MYC-
derived Vk12598 cells, a reliable MM model (i.e., t-Vk*MYC
MM; see refs.17,18). Antibiotic treatment was prolonged for the
entire duration of the experiment, and mice were followed for M-
spike appearance (Supplementary Fig. 2a). As expected17, three
weeks after transplantation the paraprotein was measurable in
sera of 80% of untreated mice, but none of the mice treated with
antibiotics showed signs of disease (Fig. 1d and Supplementary
Fig. 2b). This did not appear to be due to a direct effect of the
antibiotics on plasma cell survival, because the M-spike appeared
later in several antibiotic-treated mice (Fig. 1d). Importantly, at
the time that all the untreated t-Vk*MYC MMmice with M-spike
succumbed of the disease, all antibiotic-treated mice were still
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alive, and overall survival was improved in the latter group
(Supplementary Fig. 2b).
To further support the link between gut microbiota and MM
progression, antibiotic-treated IT mice housed in an isolator were
subjected to gavage administration of Prevotella heparinolytica,
the Prevotellaceae mostly represented in US1 (Fig. 1c), before
challenge with Vk12598 cells. As control, IT mice were infected
with P. melaninogenica, which has been associated in humans
with improved glucose metabolism under high-ﬁber diet19, and in
humanized mice with aggressive type II collagen induced
arthritis20. While in t-Vk*MYC MM mice infected with
P. heparinolytica, disease was accelerated, as demonstrated by
reduced animal survival when compared to mock-gavaged mice,
infection with P. melaninogenica prolonged animal survival
(Fig. 1e). Thus, in these experimental conditions, microbiota
constituents, and P. heparinolytica in particular, favor the
generation of a microenvironment prone to tumor cell engraft-
ment and expansion.
P. heparinolytica favors induction of IL-17-producing cells. A
causative link has been proposed between gut microbiota, chronic
inﬂammation mediated by IL-17-producing cells and cancer21–23.
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Interestingly, Prevotellaceae, which were almost only present in
US1 animals (Fig. 1c), were included among the strains able to
promote Th17 differentiation locally and at distant sites24. Thus,
we searched for IL-17-producing cells in the small intestine of
mice housed in the different conditions. A population of IL-17+
cells (Fig. 1f) was clearly detectable by ﬂow cytometry analysis in
the Peyer’s patches of all examined mice (Fig. 1g and Supple-
mentary Fig. 3a, c) in the absence of overt signs of gut inﬂam-
mation. The number and frequency of IL-17+ cells was higher in
US1 than in IT mice, and was not inﬂuenced by the disease
(Fig. 1g and Supplementary Fig. 3a, c), thus conﬁrming that the
microbiota of US1 mice and not the pathogenic background of
Vk*MYC mice favored the local expansion of IL-17-producing
cells. Also administration of P. heparinolytica but not of P. mel-
aninogenica induced expansion of IL-17+ cells in the gut of t-
Vk*MYC MM mice housed in the isolator (Fig. 1h).
To ﬁnd a correlation between gut microbiota and MM, we
looked for IL-17-producing cells in the BM, which is the
primary site of MM in both humans and Vk*MYC mice11,14, of
Vk*MYC mice housed in the different conditions. IL-17+ cells
were enriched in the BM of Vk*MYC mice when compared to
WT mice housed in the respective facilities (Fig. 1i and
Supplementary Fig. 3b, d). Accumulation of IL-17+ cells was
more pronounced in the BM of US1 versus IT Vk*MYC mice,
whereas, no difference in the number and frequency of these cells
was detected in the BM of WT mice housed in either facility
Fig. 1 P. heparinolytica favors MM progression by promoting BM accrual of IL-17+ cells. a M-spike incidence over time (weeks) in sex-matched Vk*MYC
and WT littermates housed in US1, US2 and IT animal facilities (AF) as indicated in the text. Statistical analyses (Two-way ANOVA). b Principal
component analysis of fecal microbiota from mice housed in the indicated shelters. c Mean ± SD of eight taxa in fecal microbiota between US1 (n= 8 of
biologically independent mice, US2 (n= 16) and IT (n= 8) mice relative to total number of reads recovered from each group. Statistical analyses (One-way
ANOVA (Dunn’s multiple comparison test)): *P < 0.05, **P < 0.01, ***P < 0.001. d M-spike incidence over time (days) in t-Vk*MYC MM mice either
maintained or not under antibiotics. Unpaired t test: Vehicle vs ABX up to 40 days: *P < 0.05. e Overall survival (Kaplan–Meier plot) of t-Vk*MYC MM
mice gavaged with vehicle (Vehicle), P. heparinolytica (P.h) or P. melaninogenica (P.m). log-rank (Mantel–Cox) test: Vehicle vs P.h: P= 0.0157; Vehicle vs P.
m: P= 0.0346, P.m vs P.h: P= 0.0002. f Representative dot plot of Peyer’s Patches IL-17+ cells (gated on live cells). g–j Number of Peyer’s Patches (g, h)
and BM IL-17+ cells (i, j) from mice described in a (g, i) and e (h, j), respectively. k Quantiﬁcation of α4β7+ cells gated on IL-17+ cells from the same
samples shown in i. Mean ± SD of three independent experiments. Unpaired t test: *P < 0.05; **P < 0.01. l–m Frequency of KAEDE red positive (black and
red columns) and negative (gray and green columns) Th17 cells in the spleen (l) and BM (m) of photoconverted control and diseased Kaede mice. Mean ±
SD of three independent experiments. Wilcoxon matched-pairs signed rank test; *P= 0.0156. n Survival (Kaplan–Meier plot) of t-Vk*MYC MM mice IL-17
competent (IL-17WT) or deﬁcient (IL-17KO) and maintained or not maintained under antibiotics. log-rank (Mantel–Cox) test: *P= 0.0332, **P= 0.0021. o
M-spike levels are expressed as total gamma globulins/albumin ratio (G/A) in mice within the indicated cohort. Unpaired t-test: *P < 0.05. a–e, g–o n,
number of mice used
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Fig. 2 Pro-tumoral role of IL-17 during the early phase of MM. a M-spike incidence over time (weeks) in cohorts of Vk*MYC mice either competent
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(Fig. 1i and Supplementary Fig. 3b, d). IL-17+ cells were also
enriched in the BM of t-Vk*MYC MM receiving P. heparinolytica
but not of P. melaninogenica (Fig. 1j). Thus, a pathologic
substrate is required in the BM for IL-17+ cell accumulation,
which is favored by selected bacteria.
A direct link between gut microbiota and enrichment of IL-17-
producing cells in the BM in Vk*MYC mice was suggested by the
presence of a signiﬁcant proportion of IL-17+ cells expressing the
gut-homing integrin α4β725 in the BM of Vk*MYC housed in US1
(Fig. 1k). To prove the migration of IL-17+ cells from the gut into
the BM of mice affected by MM, we took advantage of the
photoconvertible protein Kaede, which permanently changes
ﬂuorescence emission from green to red upon photoactivation,
and backcrossed Kaede-transgenic mice26, into IL-17A FP635
reporter knock in mice27, to generate Kaede/IL-17 mice. Age- and
sex-matched Kaede/IL-17 littermates were either sham-treated or
injected with Vk12598 cells, and monitored for disease progres-
sion. At the appearance of M-spike, the small intestine of all
Kaede/IL-17 littermates was photoconverted28, and the animals
were euthanized 60 h later to investigate migration of IL-17+
cells. Whereas the frequency of both Kaede red+ (i.e., IL-17+ cells
migrated from the gut) and Kaede green+ (i.e., non-
photoconverted IL-17+ cells) cells within CD3+CD4+ cells
(Supplementary Fig. 4) was similar in the spleen of both control
and Vk12598-challenged mice (Fig. 1l), Kaede red+ cells
substantially increased in the BM of tumor-bearing mice
(Fig. 1m), thus demonstrating that the presence of MM induced
migration of IL-17+ cells from the gut to the BM.
These correlative ﬁndings prompted us to look for a causative
role of microbiota-driven IL-17 in MM pathogenesis. Thus,
Vk12598 cells were either injected in age- and sex-matched IL-
17WT or IL-17KO littermates29 and treated or not with antibiotics.
Disease was substantially delayed in IL-17KO mice when
compared to WT animals (Fig. 1n). As expected (Fig. 1d),
antibiotic treatment prolonged survival of tumor bearing IL-17WT
mice (Fig. 1n), but had no effects on IL-17KO mice (Fig. 1n),
indicating that IL-17 links the microbiota to MM. These ﬁndings
also conﬁrmed that antibiotics did not have direct effects on
plasma cell survival. To further support our conclusion, Vk12598-
challenged mice were treated with either isotype control
antibodies or anti-IL17A and anti-IL17R antibodies. Treatment
with anti-IL17A and anti-IL17R antibodies delayed MM devel-
opment (Fig. 1o). Altogether, these ﬁndings support a direct link
between microbiota diversity, and expansion of a gut-born
population of IL-17+ cells that also preferentially accumulate in
the BM of mice with MM, and contribute to the pathogenesis of
the disease.
IL-17 accelerates progression of asymptomatic MM. As our
data, together with previous in vitro and in vivo results with
human samples9,30–32, suggested a role for IL-17 in favoring MM
aggressiveness, we backcrossed Vk*MYC mice into IL-17KO
congenic mice, and monitored them for disease occurrence.
Appearance of de novo disease was signiﬁcantly delayed in
Vk*MYC IL-17KO mice when compared with Vk*MYC IL-17WT
littermates (Fig. 2a). Additionally, disease progression (i.e., M-
spike ≥ 6%, which is characteristic of symptomatic, Late-MM; see
ref. 33) was delayed in Vk*MYC IL-17KO mice (Fig. 2b) when
compared to Vk*MYC IL-17WT mice, thus demonstrating that
IL-17 is also a precocious propeller of MM in this model. As
expected, WT mice never progressed to MM (Fig. 2b).
As our results suggested that IL-17 is involved in early phases
of disease (Fig. 2a), we quantiﬁed IL-17+ cells (Fig. 2c) in the BM
of both asymptomatic (Early)- and symptomatic Late-MM
Vk*MYC mice33. Surprisingly, a more signiﬁcant accumulation
of IL-17+ cells was evident in the early phases of MM than in
Late-MM (Fig. 2c).
Several immune cells produce IL-175. Indeed, the BM of
Vk*MYC mice contained measurable populations of CD3+CD4+
(Supplementary Fig. 5a), CD11b+Gr1+ (Supplementary Fig. 5b),
Nk1.1+ CD90.2+ (Supplementary Fig. 5c) and Lin−CD90
+CD127+ cells producing IL-17 (Supplementary Fig. 5d), of
which T helper type 17 (Th17) cells were the most represented
(Supplementary Fig. 5e). Again, a more signiﬁcant accumulation
of Th17 cells (Fig. 2d), and a higher ratio between Th17 cells and
neoplastic plasma cells were present in the early phases of MM
(Fig. 2e), thus supporting the concept that IL-17-producing cells
exert a relevant pathogenic role during the asymptomatic phase
and promote MM progression. BM accumulation of Th17 cells
was not a characteristic of all aged mice, or a peculiarity of mice
with M-spike, because WT mice, either with or without M-spike,
did not show enrichment of Th17 cells (Fig. 2d).
Having found accumulation of Th17 cells in the BM of
Vk*MYC mice in the early phases of MM, we sought to
investigate if such milieu favored Th17 differentiation. Thus,
naïve CD4+ T cells from TCR transgenic OTII mice34 were
cultured in the presence of BM serum from either sex-matched
and age-matched WT or Vk*MYC mice affected by Early-MM or
Late-MM. As control, naïve CD4+ T cells were cultured in the
presence of IL-6, TGF-β1, anti-IL-4, and anti-IFN-γ at concen-
trations known to induce Th17 polarization35. Th17 cells were
mostly induced by the BM sera from Vk*MYC mice (Fig. 3a),
thus conﬁrming that the BM becomes an ideal microenvironment
for Th17 cells during disease development in Vk*MYC mice. All
together, our ﬁndings suggested that IL-17 has a peculiar role in
the early phases of disease in Vk*MYC mice.
To mechanistically explain the role of IL-17-producing cells in
MM, we assessed the presence of IL-17R in Vk*MYC plasma cells
by ﬂow cytometry. As reported in human MM plasma cells31,
Vk*MYC plasma cells (Supplementary Fig. 6) also expressed both
subunits of the IL-17R (Fig. 3b), which was functional because
exposure to saturating amounts of recombinant IL-17 induced
STAT3 phosphorylation in Vk*MYC plasma cells, similarly to
saturating amounts of IL-6 (Fig. 3c, e). Interestingly, IL-17
contained in the BM sera from Vk*MYC mice induced STAT3
phosphorylation, and the addition of anti-IL17 antibodies
inhibited this phenomenon (Fig. 3d, e). Thus, the BM milieu of
Early-MM Vk*MYC mice is rich in soluble factors favoring a
Th17 switch, and sustaining neoplastic plasma cells.
Because of transgene expression, all Early-MM Vk*MYC mice
are bound to develop symptomatic MM14. In contrast, only a
fraction of patients with SMM progresses to MM36, although
their plasma cells also express IL-17R (Fig. 4a). Hypothesizing
that disease progression in Vk*MYC mice faithfully recapitulates
MM progression in SMM patients, we retrospectively measured at
SMM diagnosis IL-17 levels in the BM of a cohort of patients that
rapidly progressed to MM (i.e., <3 years), and compared these
data with those obtained from a cohort of SMM patients that did
not progress to MM in the same time frame (Supplementary
Table 1). Already at the diagnosis, SMM patients progressing to
MM within three years had much higher BM IL-17 than patients
not progressing to MM within the same time frame (Fig. 4b). IL-
17 did not further increase in MM patients either at diagnosis or
after treatment (Fig. 4b). Thus, the content of IL-17 in the BM
sera of SMM patients appears to be predictive of progression to
symptomatic disease.
IL-17 activates eosinophils in the BM of Vk*MYC mice. BM
sera of SMM patients were investigated for the content of addi-
tional inﬂammatory chemokines and cytokines. While IL-17 was
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the only one signiﬁcantly increased, several other inﬂammatory
factors attracting and activating eosinophils (i.e., RANTES, IFN-
γ, IL-4, IL-13, GM-CSF, and IL-5) showed a trend toward
enrichment in the BM sera of SMM patients rapidly progressing
to MM (Supplementary Fig. 7). Eosinophils play crucial roles
both in plasma cell homing to the BM and their retention in the
BM niche37. Herein, they speciﬁcally co-localize with plasma
cells38, and release the proliferation inducing ligand APRIL and
IL-6, essential survival factors for long-lived plasma cells37.
Eosinophils were indeed present in the BM of Vk*MYC IL-17WT
mice developing de novo MM, and their frequency increased with
disease progression (Fig. 5a and Supplementary Fig. 8a). Inter-
estingly, eosinophils were not increased in the BM of MM
Vk*MYC IL-17KO mice (Fig. 5a). When these cells were assessed
for cytokine production, which is a marker of activation,
increased frequency of IL-6+ eosinophils (Fig. 5b and
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Supplementary Fig. 8b) were found in the BM of Early-MM but
not Late-MM Vk*MYC IL-17WT mice (Fig. 5c). Again, the lack of
IL-17 prevented eosinophil accumulation in the BM of Vk*MYC
IL-17KO mice affected by MM (Fig. 5c). Finally, the eosinophil
mean ﬂuorescence intensity (MFI) for IL-6 was also increased in
Early-MM Vk*MYC mice (Fig. 5d), thus suggesting that eosi-
nophil activating factors were enriched in the BM of these mice,
particularly at early phases of disease. Consistently, we detected a
trend toward higher levels of MCP-3, which attracts and activates
eosinophils39, in the BM of Early-MM mice when compared to
Late-MM (Early-MM 376.9 ± 128.5 pg/mL (mean ± SE; n= 7);
Late-MM 100.2 ± 15.45 pg/mL (n= 5); WT 169.8 ± 46.7 (n= 5);
Supplementary Fig. 9).
As it has been reported that cytokines of the IL-17 family
induce human eosinophils to release cytokines40, we investigated
if IL-17 induced murine eosinophils to produce cytokines. Thus,
BM precursors from WT mice were induced in vitro to
differentiate to eosinophils (Supplementary Fig. 8c, d; see
ref. 41), and checked for IL-17 receptor expression. In vitro
differentiated eosinophils expressed both IL-17RA and IL-17RC
subunits (Fig. 5e), and upon stimulation with MCP-3 or IL-17,
produced both IL-6 and TNF-α (Fig. 5f, g, respectively). Finally,
we investigated if MCP-3 and/or IL-17 levels in the BM of Early-
MM mice were sufﬁcient to activate eosinophils. Indeed,
eosinophils produced more IL-6 when cultured in the presence
of BM serum from Early-MM than Late-MM or WT mice
(Fig. 5h). This phenomenon was due to the presence of MCP-3
and IL-17 because the addition of either blocking anti-CCR3 or
anti-IL-17 antibodies substantially reduced IL-6 production
(Fig. 5i).
IL-17-eosinophil axis neutralization delays MM progression.
To determine whether breaking the immune axis between IL-17
and eosinophils delayed disease progression, Early-MM Vk*MYC
mice were treated with a cocktail of monoclonal antibodies
directed against IL-17RA, IL-17A and IL-5 (Fig. 6a), the latter
being relevant for activation, recruitment and survival of eosi-
nophils42. Indeed, treatment with anti-IL-5 antibodies has been
shown to reduce eosinophil numbers in blood and BM of mice43.
Primary end point of the study was to demonstrate that the M-
spike in treated mice did not reach values > 6%, as Vk*MYC mice
with M-spike ≥ 6% are in the symptomatic MM phase33. The
combination of the 3 monoclonal antibodies signiﬁcantly delayed
disease progression, which associated with reduced accumulation
of both Th17 cells (Fig. 6c) and eosinophils (Fig. 6d) in the BM of
Vk*MYC mice. Interestingly, the combination of anti-IL17RA
and anti-IL-17A, did not signiﬁcantly impact the disease (Fig. 6b),
and treatment with only anti-IL5 antibodies, while associated
with reduced BM accrual of eosinophils (Supplementary Fig. 10c,
d), neither impacted disease progression in our MM models
(Fig. 6b and Supplementary Fig. 10a), nor affected Th17 accrual
in the BM of t-Vk*MYC MM mice (Supplementary Fig. 10b). All
together, these data support the concept that disease progression
in Vk*MYC mice is propelled by the IL-17-eosinophil axis, which
can be broken by the combination of cytokine-speciﬁc antibodies
(Fig. 7).
Discussion
Mammals have co-evolved with their surrounding microbial
environment into a complex super-organism, of which com-
mensalism and mutualism are the most advantageous relation-
ships. Conversely, altered host-microbiota interactions drive
mucosal inﬂammation, autoimmunity and aerodigestive tract
malignancies1. Our ﬁndings substantially extend this evidence,
demonstrating that P. heparinolytica, a commensal bacterium,
has a marked effect on the aggressiveness of extramucosal tumors,
and independently of gut inﬂammation. Indeed, we provide evi-
dence that accumulation within the BM of IL-17 producing cells,
a phenomenon propelled by a commensal microbe in the absence
of overt signs of gut inﬂammation, is a tumor cell-extrinsic
mechanism driving progression of MM, and possibly other
extramucosal malignancies.
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Our data also support the existence of a direct immunological
link between the gut and the BM, and, more importantly, between
the gut and the progression from asymptomatic to symptomatic
MM. Thus, we provide mechanistic insights into what has been
proposed by Enzeler and colleagues44, who showed that anti-
microbial therapy prevented solid tumor development in partially
immunodeﬁcient mice. While a substantial amount of data sup-
port a direct link between gut microbiota and gastrointestinal
cancer1, less is known on the potential role of intestinal microbes
in extramucosal tumors45. As an example, a correlation has been
clearly found between orogastric infection with the pathogen H.
hepaticus and mammary carcinoma46, through a mechanism that
requires innate immunity47. Others have elegantly linked TLR5-
signaling, microbiota, innate immunity, and extramucosal
tumors23. Thus, our data extend these previous ﬁndings showing
that in fully immunocompetent mice, non-pathogenic commensal
microbes expand a population of IL-17 producing cells, able to
migrate to the BM, and to support MM progression.
Prevotellaceae, which are known to promote Th17 differ-
entiation locally and at distant sites24, were almost only present in
US1 animals, and P. heparinolytica accelerated MM progression.
Thus, Prevotella species are primary suspects also in humans, in
which the increased abundance of these bacteria at mucosal sites
has been associated with Th17-mediated diseases including per-
iodontitis24 and rheumatoid arthritis48. Interestingly, in the
humanized HLA-DQ8 murine model, treatment with P. histicola
but not P. melaninogenica suppressed collagen-induced rheu-
matoid arthritis20, and P. histicola suppressed experimental
autoimmune encephalomyelitis by modulating IL-17 produc-
tion49. On this line, an increased abundance of Prevotella species
has been associated with reduced intestinal Th17 cell frequency
and high disease activity in multiple sclerosis50. All together, these
ﬁndings suggest that selected members of the same genus have
different disease modulating properties in different diseases51.
At the metagenomic level, the microbiota is rather redun-
dant52, and different classes of bacteria but through similar
pathways may drive cancer-promoting effects. Thus, we favor the
hypothesis that alterations in microbial richness and function
rather than true dysbiosis may affect extramucosal carcinogen-
esis2, likely through the ﬁne tuning of the immune response.
Accordingly, at pathologic examination, we did not ﬁnd relevant
signs of inﬂammation in the gut of US1 animals. Rather,
expansion of IL-17+ cells in US1 mice might be more likely
driven by a different proportion of autobiont species, which are
permanent members of the normal commensal microbiota16.
Unfortunately, loss of Prevotellaceae and additional potentially
relevant strains in US2 colony did not allow performing adequate
experiments of fecal microbiota transplantation to conclusively
demonstrate this hypothesis. We speculate that the gut micro-
biota might also impact human MM. Therefore, identiﬁcation of
the microbiome of selected groups of cancer patients, and altering
the composition of the gut microbiota, could be beneﬁcial not
only in the prevention of gastrointestinal cancer, but also in
delaying progression to symptomatic MM. It will be interesting to
investigate these issues by fecal microbiota transplantation or
selected bacteria infections in germ-free animals developing MM.
Mechanistically, we have identiﬁed the BM milieu of Vk*MYC
mice as a microenvironment rich in factors favoring eosinophils
and T cells to produce cytokines promoting neoplastic plasma cell
survival and expansion. It has been previously reported that IL-17
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is systemically rather than locally upregulated in TLR5-
unresponsive tumor-bearing mice, but only accelerates malig-
nant progression in IL-6-unresponsive tumors23. Our ﬁndings
challenge this notion, and support a promoting role for gut-
driven IL-17 also in IL-6-dependent MM. As MM is an IL-6-
driven neoplasm, it would be expected that in patients with
TLR5R392X polymorphism23, increased IL-17 serum levels would
not favor MM progression. Thus, it would be interesting to verify
if in slowly progressing SMM patients TLR5R392X polymorphism
correlates with high serum levels of IL-17.
Commensal microbes are not unique in favoring the expansion
of pathogenic Th17 cells in MM. As an example, mineral oil,
which is used in food, cosmetics and biomedicine, has been
reported to promote plasma cells neoplasms in BALB/c mice53,
through IL-654, eosinophils43, and possibly the expansion of Th17
cells55. Thus, we speculate that several environmental factors in
addition to the gut microbiota substantially inﬂuence MM pro-
gression by inducing pathogenic Th17 cells.
Prior studies have shown that Th17 cells are increased
and serum levels of IL-17 are elevated in the BM of symptomatic
MM patients9,30,31, and contribute to myeloma pathology
by sustaining malignant plasma cell proliferation and
osteoclastogenesis9,31,32. Several novel pieces of experimental
evidence contained herein extend the role of Th17 cells to the
asymptomatic phase of MM. Firstly, M-spike appearance was
substantially delayed in Vk*MYC IL-17KO mice, thus suggesting
that IL-17 is needed for the correct generation of the plasma cell
niche within the BM. Additionally, the frequency of Th17 cells
and the ratio between Th17 cells and plasma cells in the BM were
the highest in Early-MM Vk*MYC mice, which nicely correlated
with increased levels of IL-17 in the BM of SMM patients that
more rapidly progressed to MM. Together with the recent evi-
dence that Th17 cells are also enriched in the BM of some
MGUS-SMM patients56, our data support a much earlier role for
IL-17 in this neoplasm.
The pro-tumor activity of IL-17 is not limited to its direct effect
on neoplastic plasma cells expressing the IL-17R, but also through
the local activation of eosinophils. Indeed, eosinophils were
induced to produce TNF-α, IL-6 and likely others tumor-
promoting cytokines upon stimulation with IL-17. IL-6 has
long been known as a proliferative factor for MM cells. While
neoplastic plasma cells can produce IL-6, the most accepted view
is that the major source of this cytokine in the BM environment
are BM stromal cells, osteoclasts and myeloid precursors cells
from the early myeloblast to the intermediate myelocyte
maturation stages57. The latter population may contain eosino-
phils, which have been recently reported to support the early
growth of murine neoplastic plasma cells in their BM niche43.
Our data lend further credit to the role of eosinophils as key cells
in the early neoplastic plasma cell niche, but do not exclude the
role of additional IL-6-producing cells in the BM environment.
The role of eosinophils in early MM is further supported by the
ﬁnding that progression to MM was delayed in early-MM
Vk*MYC mice only if treated with the combination of antibodies
speciﬁc for IL-17, IL-17RA, and IL-5, and therapeutic efﬁcacy
correlated with a reduced BM accrual of both Th17 cells and
eosinophils. In more advanced MM, as the one reproduced in t-
Vk*MYC MM mice, anti-IL5 antibodies are ineffective, and
blocking the IL-17 signaling is sufﬁcient to delay MM. Thus, our
ﬁndings conﬁrm that eosinophils are required for the main-
tenance of neoplastic plasma cells in the BM niche43 at the early
stage of disease, and add the notion that IL-17 is one critical
cytokine in the BM microenvironment that activates eosinophils
to release factors supporting neoplastic plasma cells. As the role of
IL-5 as growth factor for myeloma plasma cells is debated43,58,
and IL-5 should not impact on BM stromal cells, one mechanism
by which anti-IL17, anti-IL-17RA, and anti-IL5 antibodies acted
in Vk*MYC mice is a reduced accrual and survival of eosinophils
and consequently of Th17 cells. While our data have highlighted a
relevant crosstalk between eosinophils and Th17 cells in the BM
of Vk*MYC mice, other cells within the tumor microenvironment
produce IL-17, and also stromal cells respond to IL-17 by pro-
ducing IL-632. Our therapeutic approach should also target these
cells.
Currently, the standard of care for patients with SMM has been
observation until symptomatic disease occurs because of the
limits in predicting disease progression13. At least two outputs of
this study address this relevant unmet clinical need. Firstly, our
data suggest that in patients with SMM a high level of IL-17 in the
BM predicts a faster progression to MM. Thus, IL-17 might
represent an early biomarker of high-risk SMM patients13. One
limit of our study is in the number of patients analyzed. A much
larger sample size is needed to assess whether IL-17, indepen-
dently from genetic properties of neoplastic plasma cells, could be
a prognostic factor at the speciﬁc stage of SMM. Results reported
herein should prompt initiating a large multicenter study to
address this medical need.
Additionally, the Food and Drug administration has recently
approved the use of anti-IL-17A and anti-IL-5 antibodies for the
treatment of immune-mediated diseases59–61. The availability of
these clinical-grade antibodies and our data suggest investigating
if targeting the IL-17-eosinophil immune axis would represent a
potential treatment for SMM patients at high risk to progress to
symptomatic MM.
Methods
Patients and BM plasma samples. Bone marrow (BM) plasma aspirates were
obtained from patients fulﬁlling the International Myeloma Working Group
(IMWG) diagnostic criteria after informed written consent, in compliance with all
the relevant ethical regulations, and with full ethical approval from the Mayo Clinic
institutional review board (authorization #12-001145). Patient’s disease staging,
collection sample date and MM diagnosis date are reported in Supplementary
Table 1. BM plasma samples were obtained by centrifugation of BM aspirates and
cryopreserved in the gas-phase of liquid nitrogen
IL-17 quantiﬁcation in human BM plasma. BM plasma samples from the Mayo
Clinic Rochester biobank were analyzed with Cytokine Human Magnetic 30-Plex
panel for Luminex platform (LHC6003M, Life Technologies, Waltham, MA) and
acquired on a Luminex 200 system equipped with with xPONENT 3.1 software
(Thermo Fisher Scientiﬁc, Waltham, MA).
Mice. All mice used in this study were on a C57BL/6 genetic background. WT
C57BL/6J mice were purchased from Charles River Breeding Laboratories, Calco
IT, or The Jackson Laboratories, Bar Harbor, ME. In Vk*MYC transgenic mice14
the activation of the transcription factor MYC, whose locus is found rearranged in
half human MM tumors62 including SMM63, occurs sporadically through the
exploitation of the physiological somatic hypermutation process in germinal center
B cells. Within a year, although with variable intensity, all mice develop a
monoclonal plasmacytosis conﬁned to the BM, a measurable serum M-spike, and
progressively show typical endorgan damage14. The model has been already vali-
dated as a faithful model to predict single agent drug activity in human MM14,17.
IL-17KO mice29 were kindly provided by Yoichiro Iwakura (Institute of Medical
Science, Tokio, Japan). To avoid genetic drifting, Vk*MYC mice were backcrossed
into IL-17KO mice for at least 6 generations before generating homozygous
Vk*MYC IL-17KO breeding pairs. Vk*MYC mice were screened by Real Time PCR
in order to identify experimental Vk*MYC+/− animals with the following primers:
primer 1 (5′-ACAGCTACGGAACTCTTGTGCGT-3′), primer 2 (5′-TCAGC-
CAAGGTTGTGAGGTTGCA-3′). C57BL/6-Tg(TcraTcrb) 1100Mjb/J (OTII)
mice34 were originally provided by William R. Heath (University of Melbourne,
Parkville, Victoria, Australia). Kaede-transgenic mice on a C57BL/6 background
were generated by Miwa Yoshihiro at the University of Tsukuba, Japan26. All these
mice were maintained under speciﬁc pathogen-free conditions (i.e., the rodents
were housed in isolated rooms, fed sterilized food and water, and routinely tested
and determined free of designated pathogens capable of interfering with research
objectives; SPF) in the San Raffaele facility and experiments were performed
according to state guidelines and approved by the European Community Guide-
lines (Authorizations #574, #1147, #863). KAEDE-transgenic mice were crossed
with IL-17A FP635 reporter knock in mice27, all on the C57BL/6 background. For
photoconversion, the small intestine of anesthetized Kaede/FP635-transgenic mice
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was subjected to lighting using a Blue Wave LED Prime UVA (Dymax), essentially
as described before28. Control mice were sham operated. These animals were
maintained under SPF conditions in the Universitätsklinikum Hamburg-
Eppendorf facility and treated in accordance with the European Community
Guidelines and with the approval of the Universitätsklinikum Hamburg-Eppendorf
Institutional Animal Care and Use Committee (authorization # 62/14). The ani-
mals reported in Fig. 1a, b, c were bred and maintained in a conventional animal
facility (i.e., the rodents were housed in dedicated rooms, and routinely tested for
designated pathogens; US1 and US2) at he Mayo Clinic Arizona, under The Mayo
Foundation Institutional and Albert Einstein College of Medicine Animal Care and
Use Committee approval #A01948. US1 colony belongs to animals generated
before 2014 from breeding between littermate Vk*MYC mice. US2 colony belongs
to animals generated after 2015 from breeding between Vk*MYC homozygous
males and C57BL/6J females purchased from the Jackson lab. Animals within the
IT colony were rederived into C57BL/6J mice from the Charles Rivers, and gen-
erated in the period 2012–2018 from breeding between Vk*MYC homozygous
mice and WT littermates. When appropriate, animal diet was speciﬁed in the
Results section. Animal facilities were constantly monitored for the presence of
relevant pathogens, and resulted free of those pathogens.
Serum protein electrophoresis. Mouse blood was periodically collected in
Eppendorf by retro-orbital sampling. Semi-automated electrophoresis was per-
formed on the Hydrasys instrument (Sebia, Lissex, France). According to the
manufacturer’s instructions, 10 µL of undiluted serum were manually applied to
the Hydragel agarose gels (Sebia). The subsequent steps: electrophoresis (pH 9.2,
20W constant current at 20 °C), drying, amidoblack staining, de-staining and ﬁnal
drying were carried out automatically. The use of Hydrasys densitometer and
Phoresis software (Sebia) for scanning resulting proﬁles provided accurate relative
concentrations (percentage) of individual protein zones. M-spike levels were cal-
culated as total gamma globulins/albumin ratio (G/A)17.
Microbiome analysis. Bacterial DNA from 50 mg of fecal material was extracted
using PowerFecal DNA Isolation Kit (MoBio) following manufacturer’s instruction
with only one minor modiﬁcation in lyses time (15 min instead of 5 min) to try to
retrieve all difﬁcult-to-lyse bacteria. Puriﬁed DNA was quantiﬁed and 200 ng per
reaction were used to amplify 16S V3-5 regions using barcoded sample-speciﬁc
primers and FastStart High Fidelity System (Roche) with this thermocycler pro-
gram: 95 °C for 5 min, 40 cycles of (95 °C for 30”, 55 °C for 45” and 72 °C for 1
min) and stored at 4 °C until usage. Amplicons were loaded on 1% agarose gel and
puriﬁed with QiaQuick Gel Extraction kit (Qiagen) and AMPure XP beads
(Beckman Coulter) to remove primer dimers, and used for emulsion-PCR fol-
lowing 454 GS Junior manufacturer’s instruction (Roche). Then, emulsion-PCR
was puriﬁed and captured beads with our correct amplicons were used to load the
instruments for the sequencing run. After quality ﬁltering, resulting sequences
(>250 bp) were analyzed with QIIME software (1.6.0). Principal component ana-
lysis (PCA) was performed on the resulting matrix of unweighted UniFrac dis-
tances between samples and statistical analysis was performed on the proportional
representation of taxa (summarized to Phyla, Class, Order, Family and Genus
levels), using unpaired Student’s t-tests.
Antibiotic treatment and challenge with tumor cells. Two weeks before I.V.
tumor cell challenge (1 × 106 Vk12598 cells derived from a MM Vk*MYC
mouse14), Ciproﬂoxacin (300 mg/L) and Metronidazole (1 g/L; Sigma-Aldrich),
known to eliminate the majority of intestinal bacteria64, were added to the drinking
water of 8–10 week old WT or IL-17KO C57BL/6J recipients, and mice were
maintained on antibiotics throughout the duration of the experiment. Mice were
monitored for M-spike appearance as described above, and sacriﬁced within
70 days. Vk12598 cells were generated in Bergsagel lab, and were not authenticated.
As these cells do not grow in vitro, they were not tested for mycoplasma
contamination.
Bacteria cultivation and mice infection. P. heparinolytica DSM 23917 and P.
melaninogenica DSM 7089 (DSMZ, Germany) were cultured in Brain Heart
Infusion (BHI) medium at 37 °C under anaerobic conditions, following manu-
facturer’s instructions. Fifty microliter of bacterial growth where then transferred
on chocolate agar plates and cultivated at 37 °C in AnaeroJar 2.5 L Jar System
(OXOID) and using AnaeroGen 2.5 L (Thermo Scientiﬁc) in order to generate an
anaerobic atmosphere. To infect mice with the selected Prevotella strains, Ampi-
cillin (1 g/L; Sigma-Aldrich), Vancomycin (0.5 g/L; Sigma-Aldrich), and Neomycin
(1 g/L; Sigma-Aldrich) were added to the drinking water of 6 week old WT C57BL/
6J and Metronidazole (2 mg/mouse; Sigma-Aldrich) was administered by oral
gavage 3 times per week. Two weeks later, antibiotic-treated animals were infected
by gavage with with P. heparinolytica or P. melaninogenica for 3 consecutive days/
week, until the end of the experiment. Each recipient mouse received an oral gavage
of 200 μL. Prevotella in the stool of infected mice was conﬁrmed by RT-PCR. After
two weeks of bacteria infection, mice were challenged I.V. with 1 × 106 Vk12598
cells. For disease monitoring, mouse blood was collected by retro-orbital sampling
once a week starting from the third week since tumor challenge, and analyzed by
Serum Protein Electrophoresis as described above.
Antibody treatments. αIL-5 (Clone TRFK5, BioxCell), or αIL-17A (Clone
P59234.19, Amgen) and αIL-17R (Clone PL-31280, Amgen) or αIL-17A, αIL-17R
and αIL-5, or isotype control (GL117, rat IgG2a) were injected i.p. (once a week for
9 weeks, 150 μg of each monoclonal antibody per mouse) in Early-MM Vk*MYC
mice. Every three weeks mice were bled for M-spike quantiﬁcation. Five days after
the last injection mice were sacriﬁced and their BM assessed for the presence of
Th17 cells and eosinophils. In experiments with the Vk12598 murine cell line, sex-
and age-matched C57BL6J or IL-17KO mice were challenged i.v. with 1 × 106
Vk12598 cells, and C57BL6J mice were weekly injected i.p. with 100 μg per mouse
of αIL-5 (Clone TRFK5, BioxCell), or αIL-17A (Clone P59234.19, Amgen) and αIL-
17R (Clone PL-31280, Amgen), their combination, or isotype control (GL117, rat
IgG2a) starting from the week of tumor challenge. Every week mice were bled for
M-spike quantiﬁcation.
Collection of BM serum and cells. Each femur devoid of epiphyses was placed
into a 0.5 mL eppendorf tube whose bottom was pierced with a 16 G needle. The
pierced eppendorf tube containing the bone was subsequently placed into a 1.5 mL
eppendorf tube and centrifuged (HeraeusTM PicoTM 17 Microcentrifuge, Ther-
moFisher Scientiﬁc, Waltham, MA USA) for few seconds. The BM pelleted
material, containing both serum (approximately 10 μL) and cells was resuspended
in 100 μL PBS, and used for ﬂow cytometry analyses. Alternatively, the resus-
pended material was centrifuged again to separate diluted serum from cells, and
stored at −80 °C.
Flow cytometry. Peyer’s Patches were removed from the small intestine, and gently
disaggregated with the help of tweezers. BM cells from the same animals were
collected as described above. Single cell suspensions were labeled with
ﬂuorochrome-conjugated monoclonal antibodies (either from BD Bioscience,
Buccinasco IT, Biolegend Europe, Uithoorn The Netherlands, or eBioscience Inc,
Prodotti Gianni, Milan, IT, or R&D Systems, Space Import-Export srl, Milano, Italy)
after neutralization of unspeciﬁc binding with FcR blocker (BD Biosciences), and
acquired by BD LSR Fortessa™(BD Biosciences). The antibodies used were: αIL17A
(clone TC11-18H10, cat 559502), αIL17RA (clone PAJ-17R cat 17-7182-80), α α4B7
(clone DATK32, cat 120607), αCD3 (clone 145-2C11, cat 100330), αCD8 (clone 53-
6.7, cat 560776), αCD4 (clone GK1.5, cat 100536), αNK1.1 (clone PK136, cat
108705), αCD90.2 (clone 30-H12, cat 105324), αCD138 (clone 281-2, cat 553714),
αpSTAT3 (clone pY705, cat 557815), αIL6 (clone MP5-20F3, cat 561367), αSiglecF
(clone E50-2440, cat 562068), αCD45 (clone 30-F11, cat 561487), αLy-6G (clone
1A8, cat 561236), αLy6C (clone HK1.4, cat 128017), αCD11b (clone M1/70, cat
101224), αCD127 (clone A019D5, cat 351303), Lin (clone 17A2/RB6-8C5/RA3-6B2/
Ter-119/M1/70, cat 133301), αCD11c (clone N418, cat 117318), αI−Ab (clone 25-9-
17, cat 114406), either from BD Bioscience, Biolegend Europe, Uithoorn The
Netherlands, or eBioscience Inc, Prodotti Gianni, Milan, IT, polyclonal αIL17RC
(cat FAB2270A) from R&D Systems, Space Import-Export srl, Milano, Italy). For
surface staining all antibodies were diluted 1:200, with the exception of αIL17RC
diluted 1:20, for intracellular staining antibodies were diluted 1:100. Data were
analyzed using the FlowJo software (TreeStar Inc, Ashland, OR, USA). Cells were
also assessed for intracellular cytokine production after 6 h at 37 °C of stimulation
with Phorbol Myristate Acetate (PMA)/ionomycin. GolgiPlug® (BD Bioscience) was
added to the samples during the last 5 hours of culture. After incubation, cells were
washed and stained for surface markers 15min at 4 °C, ﬁxed and permeabilized
with Fixation/Permeabilization Kit (BD-bioscience). Cells were then washed and
stained for intracellular markers 30min at 4 °C and acquired by FACS (BD LSR
Fortessa™). Data were analyzed using the FlowJo software (Treestar Inc).
Th17 polarization in vitro. OTII splenocytes were cultured in complete IMDM for
7 days under stimulation with anti-CD3/CD28 Dynabeads (4 × 105 beads/2 × 105
cells; Invitrogen, Thermo Fisher, Milan, IT), and in the presence of either the
combination of IL-6 (20 ng/mL, PeproTech, tebu-bio, Milan, Italy), TGF-β1 (2 ng/
mL, R&D Systems, Minneapolis, MN), anti-IL-4 (10 μg/mL, cat 554432, BD
Biosciences) and anti-IFN-γ antibodies (10 μg/mL, cat 517904, Biolegend). Alter-
natively, stimulated cells were cultured in the presence of BM serum (1:25 ﬁnal
dilution). After 7 days OTII cells were tested for intracellular cytokine production
by ﬂow cytometry.
Intracellular phospho-protein analysis by ﬂow cytometry. Vk*MYC plasma
cells were stimulated with recombinant mouse IL-6 (100 ng/mL, 30 min), or IL-17
(50 ng/mL, 20 h; Proleukin), or with BM serum (1:20) with or without the addition
of anti-IL-17A antibodies (clone: TC11-18H10.1, 3 μg/well, Biolegend) respectively,
and subsequently ﬁxed by Cyto-Fix buffer (BD Biosciences), and permeabilized in
Perm Buffer III (BD Biosciences) on ice. Staining was performed by anti-STAT3
(pY705, cat 557815, BD Biosciences) Alexa Fuor 647-conjugated antibodies and
analyzed by ﬂow cytometry.
In vitro induction of mouse bone marrow-derived eosinophils. Eosinophils were
obtained from BM precursors as described in the ref. 41. In brief, BM cells were
collected from the femurs and tibiae of WT C57BL/6J mice by ﬂushing the opened
bones with PBS (Euroclone, Pero, Italy). The BM cells were cultured at 106/mL in
medium containing RPMI 1640 (Invitrogen) with 20% FBS (Cambrex), 100 IU/mL
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penicillin and 10 μg/mL streptomycin (Cellgro), 2 mM glutamine (Invitrogen), 25
mM HEPES and 1x nonessential amino acids and 1 mM sodium pyruvate (Life
Technologies), and 50 μM 2-ME (Sigma-Aldrich) supplemented with 100 ng/mL
stem cell factor (SCF; PeproTech) and 100 ng/mL FLT3 ligand (FLT3-L; Pepro-
Tech) from days 0 to 4. On day 4, the medium containing SCF and FLT3-L was
replaced with medium containing 10 ng/mL recombinant mouse IL-5 (R&D Sys-
tems) only. On day 8, the cells were moved to new ﬂasks and maintained in fresh
medium supplemented with rmIL-5. BM eosinophils were stimulated with BM
serum (1:20) with or without the addition of anti-CCR3 (CD193, Clone: J073E5, 3
μg/well, cat 144503, Biolegend) or anti-IL-17A antibodies (clone: TC11-18H10.1, 3
μg/well, cat 506902, Biolegend).
BM serum cytokine quantiﬁcation in mice. Cytokines were quantiﬁed by the
Myriad RBD™ multiplex immunoassay (Myriad RBD, Austin, TX, USA). The sera
were 1:10 diluted with PBS, and stored at −80 ˚C until sending to Myriad RBD for
cytokine quantiﬁcation.
Statistics analyses and reproducibility. Sample size was chosen taking into
account the means of the target values between the experimental group and the
control group, the standard error and the statistical analysis used. Based on our
previous experience14,17,33 and preliminary data obtained in the Vk*MYC and t-
Vk*MYC MM models, we estimated a number of 5 and 10 animals per experimental
group for the in vitro and in vivo experiments, respectively, to ensure adequate power
(alfa= 0.05 and power= 0.80) to detect signiﬁcant variations in the measured events.
No samples or animals were excluded from the analyses. Grubb’s test was applied to
exclude outliers. Animals were always matched for sex and age. Randomization was
performed for in vivo experiments assessing the therapeutic efﬁcacy of antibodies. No
blinding was done for in vivo experiments. Data were analyzed with GraphPad Prism
version 7. The data are presented as mean ± standard deviation of the mean, indi-
vidual values as scatter plot with column bar graphs and were analyzed using Stu-
dent’s t-tests (paired or unpaired according to the experimental setting) by a two-
sided and, when indicated, followed by Wilcoxon post-test. One-way ANOVA was
used to compare three or more groups in time point analyses. Differences were
considered signiﬁcant when P < 0.05 and are indicated as NS, not signiﬁcant, *P <
0.05, **P < 0.01, ***P < 0.001. Non-parametric tests were applied when variables were
not normally distributed using the SPSS statistical software. N values represent bio-
logical replicates. Survival curves were compared using the log-rank test
(Mantel–Cox). All the statistics and reproducibility are reported in the ﬁgure legend.
Relevant data are available from the authors.
Data availability
The authors declare that the data supporting the ﬁndings of this mansucript are
available within the paper and its supplementary information. Gene expression
proﬁling data of primary SMM cells were obtained from ref. 65. The probe set used
for IL-17RA expression was 207707_at. Datasets were analyzed by Student’s t-test
directly at www.oncomine.org as 207707_at. All other remaining data supporting
the ﬁndings of this study are available from the authors upon reasonable request.
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